Sangamo Biosciences Receives Nasdaq Deficiency Notice

Sangamo Biosciences ( (SGMO) ) just unveiled an update.

On April 30, 2025, Sangamo Therapeutics, Inc. received a deficiency notice from Nasdaq due to its common stock’s bid price closing below $1.00 per share for 30 consecutive business days, which is below the required minimum for continued listing. The company has until October 27, 2025, to regain compliance by maintaining a minimum bid price of $1.00 per share for at least 10 consecutive business days. If compliance is not achieved by then, Sangamo may qualify for an additional 180-day compliance period, provided it meets other listing requirements and notifies Nasdaq of its intention to resolve the issue, potentially through a reverse stock split. Failure to comply could result in delisting, though the company can appeal such a decision.

Spark’s Take on SGMO Stock

According to Spark, TipRanks’ AI Analyst, SGMO is a Neutral.

Sangamo Biosciences presents a mixed picture. Significant financial challenges, including declining revenues and persistent negative cash flows, weigh heavily on its overall score. Technical indicators suggest a bearish trend, and valuation metrics pose concerns with a negative P/E ratio and no dividend yield. However, positive developments in strategic partnerships and neurology pipeline advancements provide some optimism, though offset by the need to secure additional financing and a partner for the Fabry program.

To see Spark’s full report on SGMO stock, click here.

More about Sangamo Biosciences

Average Trading Volume: 6,607,441

Technical Sentiment Signal: Sell

Current Market Cap: $163.7M

For a thorough assessment of SGMO stock, go to TipRanks’ Stock Analysis page.